RxDoctor Payments Data

Justyna Obara

Internal Medicine · Vineland, NJNPI 1174768048

Payments from drug & device makers

$378in general payments, 2019–2025

Across 24 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$71
  • Novartis$68
  • Exact Sciences$63
  • Merck$51
  • Boehringer Ingelheim$42
  • Lilly USA, LLC$39
  • plus $44 from 2 others

What the payments were for

  • Food & beverage$378100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$378 in reported general payments places this provider in the 50th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$67,551
Medicare patients
250
Services billed
668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$95,529
JardianceEmpagliflozin72$73,785
EliquisApixaban72$64,121
TrulicityDulaglutide24$32,790
MounjaroTirzepatide29$31,198
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$27,214
FarxigaDapagliflozin Propanediol20$23,323
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl92$18,319
Incruse ElliptaUmeclidinium Bromide44$18,304
GlyxambiEmpagliflozin/Linagliptin17$16,961
XareltoRivaroxaban13$16,157
TradjentaLinagliptin18$14,858
Breo ElliptaFluticasone/Vilanterol32$13,667
EntrestoSacubitril/Valsartan15$10,670
JanumetSitagliptin Phos/Metformin Hcl13$10,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Spiriva Respimat$42$113,565121 claims
Novo NordiskOzempic$29$95,52976 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Anoro Ellipta$71$67,946121 claims
Lilly USA, LLCTrulicity, Mounjaro$39$63,98853 claims
NovartisEntresto$68$10,67015 claims
MerckJanumet$51$10,08813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Vineland

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →